Importantly, NF-κB activation is also implicated in therapy resistance, it can inhibit chemotherapy or radiotherapy-induced apoptosis and foster tumour cell survival, as well as blunt the efficacy of immune-based therapies. Here, NFKB1 is linked to neoplasm.